Gavin Scott

Stock Analyst at JP Morgan

(n/a)

# 4,415

Out of 4,424 analysts

4

Total ratings

n/a

Success rate

-59.98%

Average return

Main Sectors:

Top Industries:

2 Stocks

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	BMEA Biomea Fusion	Downgrades: Neutral	$51 → $14	$10.65	+31.46%	3	Apr 2, 2024
	CTMX CytomX Therapeutics	Maintains: Overweight	$10 → $9	$1.98	+354.55%	1	Mar 2, 2022

Biomea Fusion

Apr 2, 2024

Downgrades: Neutral

Price Target: $51 → $14

Current: $10.65

Upside: +31.46%

CytomX Therapeutics

Mar 2, 2022

Maintains: Overweight

Price Target: $10 → $9

Current: $1.98

Upside: +354.55%